SCHEMBL3821847

SCHEMBL3821847

COc1ncc(C(N)=S)c(OC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.39
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RAD52 P43351 1/20 0.35
QPCT Q16769 1/20 0.35
QPCTL Q9NXS2 1/20 0.35
PIK3CD O00329 1/20 0.33
ABL1 P00519 1/20 0.33
EGFR P00533 1/20 0.33
HCK P08631 1/20 0.33
SRC P12931 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33
EPHB4 P54760 1/20 0.33
PRKDC P78527 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
NNMT P40261 1/20 0.33
CYP1A2 P05177 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3192298 0.82 NNMT (0.47) PLAUALDH1A1HPGDNNMTPOLB
SCHEMBL23995213 0.77 PLAU (0.36) PLAUQPCTQPCTLPIK3CDABL1
SCHEMBL2745323 0.76 TDP1 (0.51) PLAUALDH1A1HPGDQPCTQPCTL
SCHEMBL31484712 0.76 QPCT (0.35) PLAUQPCTQPCTLPIK3CDABL1
SCHEMBL2745387 0.75 GAA (0.42) PLAUALDH1A1POLBTDP1ACACB
SCHEMBL10959341 0.75 L3MBTL1 (0.37) PLAUALDH1A1QPCTQPCTLPIK3CD
Lithium Ion SCHEMBL29595061 0.74 PLAU (0.39) PLAUQPCTQPCTLNNMTCYP1A2
Lithium Ion SCHEMBL28621223 0.74 PLAU (0.39) PLAUQPCTQPCTLNNMTCYP1A2
SCHEMBL29164644 0.73 PLAU (0.42) PLAUHPGDPIK3CDABL1EGFR
SCHEMBL30822721 0.73 PLAU (0.42) PLAUHPGDPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
US-7067537-B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 PLAU 897/4885ALDH1A1 118/4885HPGD 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.